Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The cause of death in bacterial meningitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mycobacterium arosiense, an unexpected cause of osteomyelitis in a patient with sarcoidosis: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Necrotizing fasciitis and meningitis due to Streptococcus pneumoniae serotype 9 N: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Associations between blood cultures after surgery for colorectal cancer and long-term oncological outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Community-acquired meningitis caused by beta-haemolytic streptococci in adults: a nationwide population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Uncomplicated lower urinary tract infections (LUTI) are very common, and presumably around 200,000 female patients are treated for this annually in Denmark. The current Danish national clinical practice guidelines recommend pivmecillinam as a first-line drug (i.e., 400 mg t.i.d. for 3 days). Pivmecillinam is also one of the first-line drugs recommended in the international guidelines for LUTIs (i.e., 400 mg b.i.d. for 5 days). The international recommended duration is based on evidence saying that a 7-day regimen is better than a 3-day regimen. However, no data says that a 5-day regimen is superior to a 3-day regimen. With this study we aim to identify and to compare the efficacy of pivmecillinam 400 mg t.i.d in a 3-day respectively 5-day regimen, against community acquired uncomplicated LUTI, i.e., in women at the age of 18-70 year old.

METHOD/DESIGN: The general practitioner will at consultation give a suitable patient the opportunity to participate in the study. If the patient will give her consent, a double-blinded kit (i.e., the antibiotic with/without placebo, questionnaires and self-urinary samples) will be given to the patient. We aim for 161 evaluable patients in each arm.

DISCUSSION: Pivmecillinam is an excellent choice against urinary tract infections and we believe this study will fill in the gaps and strengthen the evidence on the treatment against one of the most common infections in our society. Thus, aiming to provide a more rational and ecological beneficial antimicrobial therapy.

TRIAL REGISTRATION: EudraCTno.: 2014-001321-32 .

OriginalsprogEngelsk
TidsskriftBMC Infectious Diseases
Vol/bind16
Udgave nummer1
Sider (fra-til)727
Antal sider7
ISSN1471-2334
DOI
StatusUdgivet - 1 dec. 2016

ID: 49597073